Request Information
Request Information
Mar 26 2018
Business Insider
Business Insider featured Auris’s Monarch Platform, including an animation of what happens during a bronchoscopy procedure. The article also notes that the Monarch Platform integrates the latest advancements in robotics, software, data science, and endoscope innovation, saying “Auris’s newest platform, called Monarch, is designed with the intent of transforming endoscopy, particularly in the field of lung cancer diagnosis.”
Auris aims to help diagnose lung cancer in the early stages, which is critical to battling the disease. Currently, over 90% of those diagnosed with lung cancer do not survive because the cancer is typically discovered in the advanced, inoperable stages. Auris CSO Josh DeFonzo discusses future plans for the Monarch Platform in the article, saying, “We believe that Monarch will become the go-to approach for diagnosing lung cancer in the future.”
Ultimately, the goal of the Monarch Platform is to dramatically improve patient outcomes in a field that has seen few major advances since the 1960s. Auris believes the Monarch Platform will enhance physician capabilities and lower costs to the healthcare system. The Monarch Platform allows clinicians to maneuver cameras within the patient’s body with great precision, even in difficult-to-access areas. This may eliminate the need for more invasive procedures.
The article also explains Auris’ strategy behind keeping quiet about their innovative technology over the past six years. “We didn't want to make a big stink until we had a produced a technology that actually solved a problem," said Auris Health board member Peter Hébert. Hébert also believes that Auris will lead the next phase of surgical robotics intervention. Despite their under-the-radar strategy, Auris has raised $500 million in funding from investors, including Lux Capital, Mithril Capital Management, Highland Capital, and Coatue Management.
Read More about the Monarch Platform on Business InsiderBronchoscopy:
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Urology:
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.